A Randomised trial of anti-GM-CSF Otilimab in severe COVID-19 pneumonia (OSCAR).
Jatin PatelDamon BassAlbertus BeishuizenXavier Bocca RuizHatem BoughanmiAnthony CahnHugo ColomboGerard J CrinerKatherine DavyJavier de-Miguel-DíezPablo A DoreskiSofia FernandesBruno FrançoisAnubha GuptaKate HanrottTimothy HatlenDave InmanJohn D IsaacsEmily JarvisNatalia KostinaTatiana KropotinaJean-Claude LacheradeDivya LakshminarayananPedro Martinez-AyalaCharlene McEvoyFerhat MezianiMehran MonchiSumanta MukherjeeRosana Muñoz-BermúdezJessica NeisenCiara O'SheaGaëtan PlantefeveLorrie SchifanoLee E SchwabZainab ShahidMichinori ShiranoJulia E SmithEduardo SprinzCharlotte SummersNicolas TerziMark A TidswellYuliya TrefilovaRussell WilliamsonDuncan WyncollMark LaytonPublished in: The European respiratory journal (2022)
There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.
Keyphrases
- respiratory failure
- end stage renal disease
- coronavirus disease
- ejection fraction
- sars cov
- extracorporeal membrane oxygenation
- newly diagnosed
- chronic kidney disease
- mechanical ventilation
- prognostic factors
- peritoneal dialysis
- early onset
- open label
- intensive care unit
- acute respiratory distress syndrome
- drug induced